Battered by compounders on Makena, KV seeks bankruptcy protection
This article was originally published in Scrip
Executive Summary
Blaming the US FDA for some its woes, KV Pharmaceuticals over the weekend revealed it had filed for Chapter 11 bankruptcy protection, hoping to get out from under its debt.